Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

References

Page 1

	Year	Citations
Nonparametric Estimation from Incomplete Observations Edward L. Kaplan, Paul Meier Journal of the American Statistical Association EngineeringAgingLife PredictionRare Event EstimationMortality Rates	1958	38.7K
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
EuroQol - a new facility for the measurement of health-related quality of life Health Policy Quality Of LifeLife AssessmentHealth PolicyHealth-related QualityNew Facility	1990	15.5K
Toxicity and response criteria of the Eastern Cooperative Oncology Group Martin M. Oken, Richard H. Creech, Douglass C. Tormey, American Journal of Clinical Oncology Health SciencesMedicineCancer ManagementClinical EndpointPharmacology	1982	11.4K
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer Alan Sandler, Robert J. Gray, Michael C. Perry, New England Journal of Medicine	2006	5.8K
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Journal of Clinical Oncology	2008	3.2K
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Silvia Novello, Fabrice Barlési, Raffaele Califano, Annals of Oncology MedicineCancer ManagementPulmonary BlastomaOncologyRadiation Oncology	2016	2.6K
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, Journal of Clinical Oncology	2004	2.4K
Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial Stuart Pocock, Richard Simon Biometrics Prognostic FactorsSequential Treatment AssignmentPatient SelectionRestricted RandomizationPrognosis	1975	2.3K
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia Stelmakh, The Lancet Oncology Placebo-controlled Phase 3Maintenance TreatmentMedicineCancer ManagementPharmacology	2010	1.2K

Page 1